MRSN
vs
S&P 500
MRSN
S&P 500
Over the past 12 months, MRSN has significantly outperformed S&P 500, delivering a return of +148% compared to the S&P 500's +19% growth.
Stocks Performance
MRSN vs S&P 500
Performance Gap
MRSN vs S&P 500
Performance By Year
MRSN vs S&P 500
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Mersana Therapeutics Inc
Glance View
Mersana Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing antibody drug conjugates that offer clinical benefit for cancer patients with significant unmet need. The company is headquartered in Cambridge, Massachusetts and currently employs 169 full-time employees. The company went IPO on 2017-06-28. The firm is focused on developing antibody drug conjugates (ADCs). The Company’s platforms include Dolaflexin and Dolasynthen. Its product candidates include upifitamab rilsodotin (UpRi, XMT-1536) and XMT-1592. The Company’s early stage programs include B7-H4-targeted Dolasynthen ADC, XMT-1660, as well as candidates leveraging the Immunosynthen platform. UpRi is an ADC utilizing the Company’s Dolaflexin platform and targeting NaPi2b, which is an antigen broadly expressed in ovarian cancer and non-small cell lung cancer (NSCLC) adenocarcinoma. XMT-1592 uses the Company’s Dolasynthen platform and targets NaPi2b.
